Post date October 12, 2023 Experience Genetron $126 million going-private transaction We are separately advising Genetron and the special committee of its board on the transaction
Post date January 11, 2023 Experience Sirio Pharma acquisition of a majority stake of Best Formulations We advised Sirio Pharma on the acquisition
Post date August 19, 2022 Experience Esco Aster spinoff transactions We are advising Esco Lifesciences on the spinoff
Post date August 11, 2022 Experience InSilico Medicine $35 million Series D2 financing We are advising InSilico Medicine on the financing
Post date June 7, 2022 Experience InSilico Medicine $60 million Series D financing We are advising InSilico Medicine in connection with its $60 million Series D financing
Post date May 19, 2022 Experience Laekna Therapeutics $61 million Series D financing We are advising Laekna Therapeutics in connection with its Series D financing
Post date October 29, 2021 Experience Yili Group HK$6.25 billion acquisition of 34.33% of Ausnutria Dairy We advised Yili on the acquisition of a controlling interest in Ausnutria
Post date August 5, 2021 Experience Kingsoft Cloud acquisition of controlling interests in Camelot We are advising Kingsoft Cloud in connection with the acquisition
Post date July 7, 2021 Experience Ingram Micro $7.2 billion acquisition by Platinum Equity We advised Ingram Micro on the transaction
Post date June 25, 2021 Experience Yili Group HK$1.66 billion privatization of China ZhongDi Dairy We advised Yili, the largest dairy company in China, on the takeover and delisting of ZhongDi from the HKEX